{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:35:50Z","timestamp":1792460150486,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Differ"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Ferroptosis\u2014an iron-dependent form of cell death triggered by phospholipid peroxidation\u2014has emerged as a promising therapeutic avenue in cancer treatment. Although neuroblastoma (NB) has been identified as a ferroptosis susceptible cancer, our studies reveal striking heterogeneity in ferroptosis sensitivity across high-risk NB models. Through a targeted metabolic compound screen, we identified stearoyl-CoA desaturase 1 (SCD1)\u2014a key enzyme in monounsaturated fatty acid (MUFA) synthesis\u2014as a robust ferroptosis-sensitizing target. Genetic and pharmacological inhibition of SCD1 restored ferroptosis sensitivity in resistant NB cells. Notably, high SCD1 expression correlates with poor patient prognosis. Co-treatment with arachidonic acid (AA), a polyunsaturated fatty acid (PUFA), further enhanced ferroptotic cell death via increased PUFA\/MUFA ratio. Nevertheless, neither baseline lipidomic profiles nor transcriptomes of key ferroptosis regulators reliably predicted ferroptosis sensitivity. To overcome AA\u2019s poor solubility, we engineered AA-loaded lipid nanoparticles (AA-LNPs), which selectively accumulated in high-risk NB tumors and synergized with SCD1 inhibition. This dual-sensitization strategy, termed LipidSens, significantly suppressed tumor growth and induced ferroptosis in cell-derived xenograft mouse models without systemic toxicity. Together, these findings establish MUFA synthesis blockade and PUFA enrichment as a tumor-targeted, ferroptosis-enhancing strategy, and offer a nanomedicine-based therapeutic platform for high-risk NB.<\/jats:p>","DOI":"10.1038\/s41418-025-01623-3","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T17:24:50Z","timestamp":1764177890000},"page":"903-913","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Dual lipid modulation overcomes ferroptosis resistance in high-risk neuroblastoma"],"prefix":"10.1038","volume":"33","author":[{"given":"Ine","family":"Koeken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Walravens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1588-9231","authenticated-orcid":false,"given":"Roberto","family":"Fern\u00e1ndez-Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Van Hoyweghen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iuliana","family":"Vintea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyi","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianka","family":"Golba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Dehairs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2601-2686","authenticated-orcid":false,"given":"Ali","family":"Talebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7720-5077","authenticated-orcid":false,"given":"Johannes V.","family":"Swinnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1762-5739","authenticated-orcid":false,"given":"Kaat","family":"Durinck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6955-1754","authenticated-orcid":false,"given":"Adriana","family":"Ma\u00f1as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Toyokuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerben","family":"Menschaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Fedorova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno G.","family":"De Geest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behrouz","family":"Hassannia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1633-0974","authenticated-orcid":false,"given":"Tom","family":"Vanden Berghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"1623_CR1","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature24297","volume":"551","author":"MJ Hangauer","year":"2017","unstructured":"Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature. 2017;551:247\u201350.","journal-title":"Nature"},{"key":"1623_CR2","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.ccell.2018.03.017","volume":"33","author":"J Tsoi","year":"2018","unstructured":"Tsoi J, Robert L, Paraiso K, Galvan C, Sheu KM, Lay J, et al. Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress. Cancer Cell. 2018;33:890\u2013904.e5.","journal-title":"Cancer Cell"},{"key":"1623_CR3","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nature23007","volume":"547","author":"VS Viswanathan","year":"2017","unstructured":"Viswanathan VS, Ryan MJ, Dhruv HD, Gill S, Eichhoff OM, Seashore-Ludlow B, et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017;547:453\u20137.","journal-title":"Nature"},{"key":"1623_CR4","first-page":"1060","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM. Ferroptosis: an iron- dependent form of non-apoptotic. Cell Death Cell. 2012;149:1060\u201372.","journal-title":"Cell Death Cell"},{"key":"1623_CR5","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1172\/JCI99032","volume":"128","author":"B Hassannia","year":"2018","unstructured":"Hassannia B, Wiernicki B, Ingold I, Qu F, Herck SV, Tyurina YY, et al. Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma. J Clin Investig. 2018;128:3341\u201355.","journal-title":"J Clin Investig"},{"key":"1623_CR6","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s43018-022-00355-4","volume":"3","author":"H Alborzinia","year":"2022","unstructured":"Alborzinia H, Fl\u00f3rez AF, Kreth S, Br\u00fcckner LM, Yildiz U, Gartlgruber M, et al. MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis. Nat Cancer. 2022;3:471\u201385.","journal-title":"Nat Cancer"},{"key":"1623_CR7","doi-asserted-by":"crossref","unstructured":"Alborzinia H, Chen Z, Yildiz U, Freitas FP, Vogel FCE, Varga JP, et al. LRP8-mediated selenocysteine uptake is a targetable vulnerability in MYCN-amplified neuroblastoma. EMBO Mol Med. 2023;15:e18014.","DOI":"10.15252\/emmm.202318014"},{"key":"1623_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01090-6","volume":"9","author":"A Ma\u00f1as","year":"2025","unstructured":"Ma\u00f1as A, Seger A, Adamska A, Smyrilli K, Siaw JT, Radke K, et al. Targeted ferroptosis induction enhances chemotherapy efficacy in chemoresistant neuroblastoma. NPJ Precis Oncol. 2025;9:311.","journal-title":"NPJ Precis Oncol"},{"key":"1623_CR9","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(07)60983-0","volume":"369","author":"JM Maris","year":"2007","unstructured":"Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet (Lond, Engl). 2007;369:2106\u201320.","journal-title":"Lancet (Lond, Engl)"},{"key":"1623_CR10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrc1014","volume":"3","author":"GM Brodeur","year":"2003","unstructured":"Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3:203\u201316.","journal-title":"Nat Rev Cancer"},{"key":"1623_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102964","volume":"79","author":"J Nong","year":"2025","unstructured":"Nong J, Su C, Li C, Wang C, Li W, Li Y, et al. Global, regional, and national epidemiology of childhood neuroblastoma (1990\u20132021): a statistical analysis of incidence, mortality, and DALYs. eClinicalMedicine. 2025;79:102964.","journal-title":"eClinicalMedicine"},{"key":"1623_CR12","doi-asserted-by":"crossref","unstructured":"Maris JM Recent advances in neuroblastoma. New Engl J Med [Internet]. 2010;362:2202\u201311. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20558371.","DOI":"10.1056\/NEJMra0804577"},{"key":"1623_CR13","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1200\/JCO.21.00278","volume":"39","author":"MS Irwin","year":"2021","unstructured":"Irwin MS, Naranjo A, Zhang FF, Cohn SL, London WB, Gastier-Foster JM, et al. Revised neuroblastoma risk classification system: a report from the Children\u2019s Oncology Group. J Clin Oncol: J Am Soc Clin Oncol. 2021;39:3229\u201341.","journal-title":"J Clin Oncol: J Am Soc Clin Oncol"},{"key":"1623_CR14","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.3390\/cancers12113273","volume":"12","author":"H Yang","year":"2020","unstructured":"Yang H, Zhao L, Gao Y, Yao F, Marti TM, Schmid RA, et al. Pharmacotranscriptomic analysis reveals novel drugs and gene networks regulating ferroptosis in cancer. Cancers. 2020;12:3273.","journal-title":"Cancers"},{"key":"1623_CR15","doi-asserted-by":"crossref","unstructured":"Berndt C, Alborzinia H, Amen VS, Ayton S, Barayeu U, Bartelt A, et al. Ferroptosis in health and disease. Redox Biol. 2024;103211.","DOI":"10.1016\/j.redox.2024.103211"},{"key":"1623_CR16","doi-asserted-by":"crossref","unstructured":"Pope LE, Dixon SJ. Regulation of ferroptosis by lipid metabolism. Trends Cell Biol. 2023","DOI":"10.1016\/j.tcb.2023.05.003"},{"key":"1623_CR17","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.chembiol.2018.11.016","volume":"26","author":"L Magtanong","year":"2019","unstructured":"Magtanong L, Ko PJ, To M, Cao JY, Forcina GC, Tarangelo A, et al. Exogenous monounsaturated fatty acids promote a ferroptosis-resistant cell state. Cell Chem Biol. 2019;26:420\u201332.e9.","journal-title":"Cell Chem Biol"},{"key":"1623_CR18","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nrc.2016.89","volume":"16","author":"F R\u00f6hrig","year":"2016","unstructured":"R\u00f6hrig F, Schulze A. The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer. 2016;16:732\u201349.","journal-title":"Nat Rev Cancer"},{"key":"1623_CR19","doi-asserted-by":"publisher","first-page":"8117","DOI":"10.1158\/0008-5472.CAN-09-3871","volume":"70","author":"E Rysman","year":"2010","unstructured":"Rysman E, Brusselmans K, Scheys K, Timmermans L, Derua R, Munck S, et al. De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res. 2010;70:8117\u201326.","journal-title":"Cancer Res"},{"key":"1623_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.102128","volume":"24","author":"MV Ruiz-P\u00e9rez","year":"2021","unstructured":"Ruiz-P\u00e9rez MV, Sainero-Alcolado L, Oliynyk G, Matuschek I, Balboni N, Ubhayasekera SJKA, et al. Inhibition of fatty acid synthesis induces differentiation and reduces tumor burden in childhood neuroblastoma. Iscience. 2021;24:102128.","journal-title":"Iscience"},{"key":"1623_CR21","doi-asserted-by":"crossref","unstructured":"Veeckmans G, San EV, Berghe TV. A Guide to ferroptosis, the biological rust of cellular membranes. FEBS J. 2023;","DOI":"10.1111\/febs.16993"},{"key":"1623_CR22","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1152\/physrev.00031.2024","volume":"105","author":"Z(\u90d1\u5609\u70c1) Jiashuo","year":"2025","unstructured":"Jiashuo Z(\u90d1\u5609\u70c1), Conrad M. Ferroptosis: when metabolism meets cell death. Physiol Rev. 2025;105:651\u2013706.","journal-title":"Physiol Rev"},{"key":"1623_CR23","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/s44222-024-00203-3","volume":"2","author":"A Dasgupta","year":"2024","unstructured":"Dasgupta A, Sofias AM, Kiessling F, Lammers T. Nanoparticle delivery to tumours: from EPR and ATR mechanisms to clinical impact. Nat Rev Bioeng. 2024;2:714\u20136.","journal-title":"Nat Rev Bioeng"},{"key":"1623_CR24","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.chembiol.2019.01.008","volume":"26","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Tan H, Daniels JD, Zandkarimi F, Liu H, Brown LM, et al. Imidazole ketone erastin induces ferroptosis and slows tumor growth in a mouse lymphoma model. Cell Chem Biol. 2019;26:623\u201333.e9.","journal-title":"Cell Chem Biol"},{"key":"1623_CR25","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adk7329","volume":"10","author":"M\u00e4ssenhausen","year":"2024","unstructured":"M\u00e4ssenhausen, von A, Schlecht MN, Beer K, Maremonti F, Tonnus W, et al. Treatment with siRNAs is commonly associated with GPX4 up-regulation and target knockdown-independent sensitization to ferroptosis. Sci Adv. 2024;10:eadk7329.","journal-title":"Sci Adv"},{"key":"1623_CR26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nchembio.2238","volume":"13","author":"VE Kagan","year":"2017","unstructured":"Kagan VE, Mao G, Qu F, Pedro J, Angeli F, Doll S, et al. Oxidized arachidonic\/adrenic phosphatidylethanolamines navigate cells to ferroptosis. Nat Chem Biol. 2017;13:81\u201390.","journal-title":"Nat Chem Biol"},{"key":"1623_CR27","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.cell.2024.01.030","volume":"187","author":"B Qiu","year":"2024","unstructured":"Qiu B, Zandkarimi F, Bezjian CT, Reznik E, Soni RK, Gu W, et al. Phospholipids with two polyunsaturated fatty acyl tails promote ferroptosis. Cell. 2024;187:1177\u20131190.e18.","journal-title":"Cell"},{"key":"1623_CR28","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.chembiol.2015.11.016","volume":"23","author":"K Shimada","year":"2016","unstructured":"Shimada K, Hayano M, Pagano NC, Stockwell BR. Cell-line selectivity improves the predictive power of pharmacogenomic analyses and helps identify NADPH as biomarker for ferroptosis sensitivity. Cell Chem Biol. 2016;23:225\u201335.","journal-title":"Cell Chem Biol"},{"key":"1623_CR29","doi-asserted-by":"publisher","first-page":"5355","DOI":"10.1158\/0008-5472.CAN-19-0369","volume":"79","author":"L Tesfay","year":"2019","unstructured":"Tesfay L, Paul BT, Konstorum A, Deng Z, Cox AO, Furdui CM, et al. Steroyl-CoA Desaturase 1 (SCD1) protects ovarian cancer cells from ferroptotic cell death. Cancer Res. 2019;79:5355\u201366.","journal-title":"Cancer Res"},{"key":"1623_CR30","doi-asserted-by":"publisher","first-page":"31189","DOI":"10.1073\/pnas.2017152117","volume":"117","author":"J Yi","year":"2020","unstructured":"Yi J, Zhu J, Wu J, Thompson CB, Jiang X. Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis. Proc Natl Acad Sci. 2020;117:31189\u201397.","journal-title":"Proc Natl Acad Sci"},{"key":"1623_CR31","doi-asserted-by":"crossref","unstructured":"Schwab A, Rao Z, Zhang J, Gollowitzer A, Siebenk\u00e4s K, Bindel N, et al. Zeb1 mediates EMT\/plasticity-associated ferroptosis sensitivity in cancer cells by regulating lipogenic enzyme expression and phospholipid composition. Nat Cell Biol. 2024;1\u201312.","DOI":"10.1038\/s41556-024-01464-1"},{"key":"1623_CR32","doi-asserted-by":"crossref","unstructured":"Samovich SN, Mikulska-Ruminska K, Dar HH, Tyurina YY, Tyurin VA, Souryavong AB, et al. Strikingly high activity of 15-lipoxygenase towards di-polyunsaturated arachidonoyl\/adrenoyl-phosphatidylethanolamines generates peroxidation signals of ferroptotic cell death. Angew Chem Int Ed. 2024;e202314710.","DOI":"10.1002\/anie.202314710"},{"key":"1623_CR33","doi-asserted-by":"crossref","unstructured":"Li EQ, Zhao W, Zhang C, Qin LZ, Liu SJ, Feng ZQ, et al. Synthesis and anti-cancer activity of ND-646 and its derivatives as acetyl-CoA carboxylase 1 inhibitors. Eur J Pharm Sci [Internet]. 2019;137:105010. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31325544","DOI":"10.1016\/j.ejps.2019.105010"},{"key":"1623_CR34","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/nm.4181","volume":"22","author":"RU Svensson","year":"2016","unstructured":"Svensson RU, Parker SJ, Eichner LJ, Kolar MJ, Wallace M, Brun SN, et al. Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models. Nat Med [Internet]. 2016;22:1108\u201319. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27643638.","journal-title":"Nat Med [Internet]"},{"key":"1623_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31963-4","volume":"13","author":"C Bartolacci","year":"2022","unstructured":"Bartolacci C, Andreani C, Vale G, Berto S, Melegari M, Crouch AC, et al. Targeting de novo lipogenesis and the lands cycle induces ferroptosis in KRAS-mutant lung cancer. Nat Commun. 2022;13:4327.","journal-title":"Nat Commun"},{"key":"1623_CR36","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41556-020-0461-8","volume":"22","author":"H Lee","year":"2020","unstructured":"Lee H, Zandkarimi F, Zhang Y, Meena JK, Kim J, Zhuang L, et al. Energy-stress-mediated AMPK activation inhibits ferroptosis. Nat Cell Biol. 2020;22:225\u201334.","journal-title":"Nat Cell Biol"},{"key":"1623_CR37","first-page":"6387","volume":"46","author":"Y Matsumura","year":"1986","unstructured":"Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46:6387\u201392.","journal-title":"Cancer Res"},{"key":"1623_CR38","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.addr.2020.06.005","volume":"157","author":"J Fang","year":"2020","unstructured":"Fang J, Islam W, Maeda H. Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers. Adv Drug Deliv Rev. 2020;157:142\u201360.","journal-title":"Adv Drug Deliv Rev"},{"key":"1623_CR39","doi-asserted-by":"publisher","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","volume":"118","author":"CU Louis","year":"2011","unstructured":"Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, et al. Antitumor activity and long-term fate of chimeric antigen receptor\u2013positive T cells in patients with neuroblastoma. Blood. 2011;118:6050\u20136.","journal-title":"Blood"},{"key":"1623_CR40","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.1882","volume":"14","author":"MA Pule","year":"2008","unstructured":"Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14:1264\u201370.","journal-title":"Nat Med"},{"key":"1623_CR41","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","volume":"363","author":"AL Yu","year":"2010","unstructured":"Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363:1324\u201334.","journal-title":"N Engl J Med"},{"key":"1623_CR42","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41586-020-2732-8","volume":"585","author":"Y Zou","year":"2020","unstructured":"Zou Y, Henry WS, Ricq EL, Graham ET, Phadnis VV, Maretich P, et al. Plasticity of ether lipids promotes ferroptosis susceptibility and evasion. Nature. 2020;585:603\u20138.","journal-title":"Nature"},{"key":"1623_CR43","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.devcel.2025.02.004","volume":"60","author":"WC Lee","year":"2025","unstructured":"Lee WC, Dixon SJ. Mechanisms of ferroptosis sensitization and resistance. Dev Cell. 2025;60:982\u201393.","journal-title":"Dev Cell"},{"key":"1623_CR44","doi-asserted-by":"publisher","unstructured":"Beatty A, Singh T, Tyurina YY, Nicolas E, Maslar K, Zhou Y, et al. Conjugated linolenic fatty acids trigger ferroptosis in triple-negative breast cancer. https:\/\/doi.org\/10.1101\/556084.","DOI":"10.1101\/556084"},{"key":"1623_CR45","doi-asserted-by":"publisher","first-page":"15374","DOI":"10.18632\/aging.103598","volume":"12","author":"C Wang","year":"2020","unstructured":"Wang C, Shi M, Ji J, Cai Q, Zhao Q, Jiang J, et al. Stearoyl-CoA desaturase 1 (SCD1) facilitates the growth and anti-ferroptosis of gastric cancer cells and predicts poor prognosis of gastric cancer. Aging. 2020;12:15374\u201391.","journal-title":"Aging"},{"key":"1623_CR46","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","volume":"160","author":"Y(Chezy) Barenholz","year":"2012","unstructured":"Barenholz Y(Chezy). Doxil\u00ae\u2014The first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160:117\u201334.","journal-title":"J Control Release"},{"key":"1623_CR47","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejca.2020.04.031","volume":"135","author":"L Amoroso","year":"2020","unstructured":"Amoroso L, Castel V, Bisogno G, Casanova M, Marquez-Vega C, Chisholm JC, et al. Phase II results from a phase I\/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: a collaboration with the European Innovative Therapies for Children with Cancer Network. Eur J Cancer. 2020;135:89\u201397.","journal-title":"Eur J Cancer"}],"container-title":["Cell Death &amp; Differentiation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41418-025-01623-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-025-01623-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-025-01623-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T08:47:56Z","timestamp":1778230076000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41418-025-01623-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1623"],"URL":"https:\/\/doi.org\/10.1038\/s41418-025-01623-3","relation":{},"ISSN":["1350-9047","1476-5403"],"issn-type":[{"value":"1350-9047","type":"print"},{"value":"1476-5403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TVB owns patents related to ferroptosis inhibitors and is the founder of FiriX Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}